GlobeNewswire

Unprecedented worldwide support for the Global Partnership for Education and addressing the global learning crisis

Dela

DAKAR, Senegal, Feb. 03, 2018 (GLOBE NEWSWIRE) -- Ten current and three former heads of state and more than 60 ministers gathered at the Global Partnership for Education (GPE) Financing Conference, making this the highest-level education financing event of its kind.

The conference, co-hosted by President Macky Sall of the Republic of Senegal and President Emmanuel Macron of the French Republic, marks the first time an education financing conference has been hosted by a G7 leader and the president of a developing country.

More than 1200 participants attended including leaders from UNESCO, UNICEF, the World Bank, civil society, philanthropic foundations and the private sector. Rihanna, GPE's Global Ambassador supported by Global Citizen, also participated.

The size and nature of the attendance at the conference was a visible demonstration of the strengthened global political will to ensure every child is in school and learning. This heightened momentum will enable the Global Partnership for Education to reach the goal of providing US$2 billion a year by 2020 for education planning and delivery to support children's learning in developing countries.

Donor countries pledged US$2.3 billion in financing to GPE. This is a substantial increase in funding compared to the US$1.3 billion contributed over the past three years. In addition, several donor countries have indicated their intention to pledge further funds over the course of the financing period.

The biggest source of education financing comes from developing countries themselves. More than 50 developing countries announced they would increase public expenditures for education for the period of 2018 to 2020 to a total of US$110 billion, compared to US$80 billion between 2015 and 2017.

GPE encourages developing countries to increase their share of education spending to 20% of their overall budget. Of those governments committing today, over two-thirds will have reached that goal by 2020.

"I am energized by the generosity and determination we have seen here today to ensure every child and young person has access to a quality education. After today's commitments, we are seeing a clear trend to seriously address the global learning crisis," said Julia Gillard, Board Chair of the Global Partnership for Education and former Prime Minister of Australia. "The success of the conference marks a turning point for global political support for education financing and brings a new breadth and depth to our partnership."

At the conference, the United Arab Emirates joined GPE, becoming the first Arab donor and pledging US$100 million. Senegal, in addition to pledging to increase its own expenditure on education, became GPE's first African donor. The Netherlands and Spain renewed their involvement, and China attended for the first time.

"The unprecedented support today means that the Global Partnership for Education can continue to focus on the most excluded and vulnerable children and work to extend assistance to up to 89 countries, which are home to 870 million children and 78 percent of the world's out-of-school children," said Alice Albright, Chief Executive Officer, Global Partnership for Education.

The Global Partnership for Education's funding model is a catalyst for education investment, working hand in hand with governments of low-income and lower middle-income countries to strengthen their education systems. The Global Partnership for Education supports governments to develop robust national education plans so that funds can then be channeled into their priority areas with confidence that they will contribute to improved quality of education for all children. 

The conference was sponsored by: Ecobank, the Pan African Bank; Fondation Sonatel; and Altissia, and supported by Girls Not Brides; Global Campaign for Education; Global Citizen; Malala Fund; ONE; Plan International; RESULTS; and Women Deliver.

Video: https://www.youtube.com/gpforeducation

Conference Online Media Center:  https://www.globalpartnership.org/funding/replenishment/gpe-replenishment-media

Media contact

Alexandra Humme, ahumme@globalpartnership.org, tel: + 1 202 492 8890

For more information on the work of the Global Partnership for Education visit:

www.globalpartnership.org 
facebook.com/globalpartnership
twitter.com/gpforeducation

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ba917718-02da-4e22-8af8-d9e0c51153da




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Global Partnership for Education via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum